CLRB Stock, Cellectar Biosciences Inc. Information

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether PLE platform technology as a targeted delivery and retention vehicle, Cellectar s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I CLR is a small molecule, broad spectrum, cancer targeted PET imaging agent. A Phase II trial evaluating I CLR in glioblastoma is expected to be completed in . Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across solid tumor indications. I CLR is a small molecule, broad spectrum, cancer targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose escalation trial of I CLR in patients with advanced solid tumors is anticipated in the first quarter of . CLR is a preclinical, cancer targeted, non radioactive optical imaging agent for intraoperative tumor margin illumination and non invasive tumor imaging. For additional information please visit www.cellectar.com